Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G.
Allen E, et al. Among authors: tawney j.
Sci Transl Med. 2017 Apr 12;9(385):eaak9679. doi: 10.1126/scitranslmed.aak9679.
Sci Transl Med. 2017.
PMID: 28404866
Free PMC article.